Suzuki T, Shimizu T, Imai K, Yamanaka H, Suzuki K, Takahashi H
Department of Urology, Gumma University School of Medicine.
Hinyokika Kiyo. 1989 Feb;35(2):259-63.
We studied the progressive factors for incidental carcinoma of the prostate of 38 patients. Effects of anti-androgen drugs for the development of incidental carcinoma were examined. There were no statistical differences with age, tumor size, histopathological grade, or invasion of BPH capsule. However, the tumor progression rate was high for a tumor size of more than 10 mm or poorly differentiated adenocarcinoma. Therefore, tumor progression was related with tumor size and histopathological grade. Of 15 patients with stage A1 disease, two patients had tumor progression. Patients with stage A1 disease are being followed with no treatment, but radical treatment may be necessary for young men. Patients with stage A2 disease must be treated with radical prostatectomy, radiation therapy or hormone therapy case by case. None of the patients who were treated with anti-androgen drugs had stage A1 disease. Patients not treated had stage A1 and A2 diseases. Anti-androgen drugs may have inhibited the development of stage A1 disease.
我们研究了38例前列腺偶发癌的进展因素。检测了抗雄激素药物对偶发癌发生发展的影响。在年龄、肿瘤大小、组织病理学分级或前列腺增生包膜侵犯方面无统计学差异。然而,肿瘤大小超过10mm或低分化腺癌的肿瘤进展率较高。因此,肿瘤进展与肿瘤大小和组织病理学分级有关。在15例A1期疾病患者中,2例出现肿瘤进展。A1期疾病患者未接受治疗正在随访,但年轻男性可能需要根治性治疗。A2期疾病患者必须根据具体情况接受根治性前列腺切除术、放射治疗或激素治疗。接受抗雄激素药物治疗的患者均无A1期疾病。未接受治疗的患者有A1期和A2期疾病。抗雄激素药物可能抑制了A1期疾病的发展。